1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Agenus PD-1 Down But Not Out With Cervical Cancer BLA Withdrawal

 
• By Alaric DeArment

The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.

Digital illustration of Cancer cell in colour background
Agenus said it would withdraw the BLA for its PD-1 inhibitor, balstilimab, in 2L cervical cancer • Source: Shutterstock

The full approval of Merck & Co., Inc.’s PD-1 inhibitor Keytruda (pembrolizumab) in cervical cancer months ahead of its target action date has led Agenus Inc. to pull the approval application for its own PD-1 inhibitor, balstilimab, in second-line disease. But while it marks a significant setback for the company, its overall development program for the drug will continue.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

Arbele Leverages Rights As It Drugs Proprietary CDH17 Target

 
• By Dexter Jie Yan

Arbele has emerged as a global leader in the Cadherin 17 area, not only in clinical progress but also for its “secret recipe” for application in T-cell engagers, its CEO tells Scrip.

Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC

 
• By Alaric DeArment

The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

More from Anticancer

Telix Moves TLX101 Forward On Encouraging Early Brain Cancer Data

 
• By Alaric DeArment

The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.